Figure 5
From: Multi-omics data integration reveals novel drug targets in hepatocellular carcinoma
A. Immunoblot analysis indicates increased Hdac4 and Yap1 and reduced Sirt1 protein levels in L-dKO tumors (n = 4) compared to age-matched littermate control (liver samples from control mice (n = 4)). B. Quantification of immunoblot (from Fig. 5A) indicates increased Hdac4 (****P = 0.000004) and increased Yap1 (**P = 0.0016) and reduced Sirt1 (**P = 0.0025) expression in tumors compared to age-matched control littermates (band intensities in each lane are normalized to intensity of corresponding total Akt protein levels). P values are from a two-sided unpaired t-test. Data is mean ± s.d. C. Immunoblot analysis indicates increased Hdac4 and Yap1 and reduced Sirt1 protein levels in liver tissue from patients with HCC compared to adjacent non- tumor liver tissue in a total of n = 5 HCC patients. D. Quantification of immunoblot (from Fig. 5C) indicates increased Hdac4 (*P = 0.040032) and increased Yap1 (*P = 0.013164) in 5 out of 5 patients and reduced Sirt1 (**P = 0.007155) in 4 out of 5 patients. 1 out of 5 patients did not show a reduction in Sirt1 protein levels (circles in red) and has been excluded in the significance analysis. (band intensities in each lane are normalized to intensity of corresponding total Akt protein levels). P values are from a two-sided paired t-test. Data are mean ± standard deviation. E. Lis1 mRNA is downregulated in liver cancer. Graphical representation of Lis1 mRNA regulation in n=373 liver cancer patients downloaded from TCGA (provisional) (accessed on 10.10.2018). Each circle represents a patient. 2 fold regulation of mRNA expression compared to control was used to define up regulation (log2 fold change ≥ 1) or down regulation (log2 fold change ≤ 1). Lis1 mRNA expression is downregulated in 47%, unchanged in 43% and upregulated in 10% of the liver cancer patients. The full length images are shown in supplementary figure 5 (Figure S5)